Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Ebiomedicine|December 12, 2024
An ultra-early, transient interferon-associated innate immune response associates with protection from SARS-CoV-2 infection despite exposureJoe Fenn, Kieran Madon, Emily Conibear, et al.
The Lancet. Infectious Diseases|November 10, 2021
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort studyAnika Singanayagam, Seran Hakki, Jake Dunning, et al.
The European Respiratory Journal|November 26, 2021
Broadening symptom criteria improves early case identification in SARS-CoV-2 contactsHamish Houston, Seran Hakki, Timesh D Pillay, et al.
Mucosal Immunology|November 23, 2023
A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodiesDana Costigan, Joe Fenn, Sandi Yen, et al.
The Lancet. Respiratory Medicine|August 21, 2022
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort studySeran Hakki, Jie Zhou, Jakob Jonnerby, et al.
Nature|September 4, 2012
Interaction landscape of membrane-protein complexes in Saccharomyces cerevisiaeMohan Babu, James Vlasblom, Shuye Pu, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 6, 2024
Validated machine learning tools to distinguish immune checkpoint inhibitor, radiotherapy, COVID-19 and other infective pneumonitisSumeet Hindocha, Benjamin Hunter, Kristofer Linton-Reid, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
The Lancet. Microbe|April 9, 2023
Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort studyNieves Derqui, Aleksandra Koycheva, Jie Zhou, et al.
Pageof 20